COMPASS THERAPEUTICS (CMPX) reported significant investment during Q3 Fiscal 2025, successfully funding operations and portfolio expansion through substantial equity raising.
Financial Performance (9M Ended 9/30/2025): The Net Loss widened to $(50.8 million) from \((34.3 million)\) year-over-year, driven by increased operating costs and zero reported licensing revenue (vs. \(0.85 million prior). Total R&D expenses rose 44% to **\)42.3 million**, heavily allocated to Tovecimig (\(17.2M) and initiation of CTX-10726 studies (\)6.7M). Net Loss Per Share worsened to \((0.34)\).
**Liquidity and Ba
...